Trial Profile
Investigator-Initiated Phase I/II Clinical Trial of Selinexor (KPT-330) and Pegylated Liposomal Doxorubicin for Relapsed and Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs Selinexor (Primary) ; Dexamethasone; Doxorubicin liposomal
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 12 Dec 2023 Results assessing the cellular mechanisms of SELI resistance leading to an immunogenic cell state presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 29 Dec 2022 Status changed from active, no longer recruiting to completed.
- 09 May 2022 Planned End Date changed from 1 Apr 2022 to 1 Apr 2023.